Estimating the full public health value of vaccination

Gessner, Bradford D.; Kaslow, David C.; Louis, Jacques; Neuzil, Kathleen M.; O'Brien, Katherine L.; Picot, Valentina; Pang, Tikki; Parashar, Umesh D.; Saadatian‐Elahi, Mitra; Nelson, Christopher P.

doi:10.1016/j.vaccine.2017.09.048

Cited by 59 publications

(57 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It also assists in setting the appropriate target product profile, product development and regulatory strategy and ultimately proposes the advocacy, policy and public health activities needed to ensure demand, adoption, and implementation practices. 44 In recent years, the scientific and vaccine community of thought-leaders have advocated that a FPHVP should not only include assessments related to individual benefit-risks or individually randomized clinical trials but that the translational science for a public health intervention should be more comprehensive and include the evaluation of the population impact and community benefits-risks. As elegantly described by Gessner et al, the FPHVP of vaccination should include a wider scope of vaccine benefits and not limit the assessment based solely on economic vaccination-set health benefits but rather include the non-health benefits including productivity, health-risk reduction, equity/fairness and fiscal impacts.…”

Section: Institute Of Allergy and Infectious Diseases (Nih-niaid) Andmentioning

confidence: 99%

“…As elegantly described by Gessner et al, the FPHVP of vaccination should include a wider scope of vaccine benefits and not limit the assessment based solely on economic vaccination-set health benefits but rather include the non-health benefits including productivity, health-risk reduction, equity/fairness and fiscal impacts. 44 For the NTDs and emerging or emergent infectious diseases, these processes and decisions have been hampered by the perception that the development costs are substantial and that there is an implicit market failure leading to no or limited financial returns on investments.…”

Section: Institute Of Allergy and Infectious Diseases (Nih-niaid) Andmentioning

confidence: 99%

See 1 more Smart Citation

“Running the Gauntlet”: Formidable challenges in advancing neglected tropical diseases vaccines from development through licensure, and a “Call to Action”

Bottazzi

Hotez

2019

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Translational science for new biotechnologies (e.g. drugs, vaccines, devices, or diagnostics) depend on the development of a robust ‘business case’. This is driven by complex scientific, technical, logistical, financial and operational elements to determine the feasibility and probability of traversing the “valleys of death” leading to licensure. The potential results in terms of profitability and financial realization, called ‘product value proposition’ play a crucial role in establishing incentives for investment during and after development. With this review, our goal is to summarize the challenges in taking vaccines against neglected tropical diseases (NTDs) from development through licensure and provide a perspective that these vaccines can have measurable public health and economic profitability and market success. Understanding these processes and its challenges would open the opportunity to accelerate and advance these essential NTD vaccines through the last mile towards licensure and for the delivery to afflicted populations in low- and middle-income countries.

show abstract

Section: Institute Of Allergy and Infectious Diseases (Nih-niaid) Andmentioning

confidence: 99%

Section: Institute Of Allergy and Infectious Diseases (Nih-niaid) Andmentioning

confidence: 99%

“Running the Gauntlet”: Formidable challenges in advancing neglected tropical diseases vaccines from development through licensure, and a “Call to Action”

Bottazzi

Hotez

2019

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…FPHVPs go beyond the customary perspective of direct individual health benefits and attempt to capture the full economic and societal benefits of vaccination. To prevent a lag between licensure and uptake, they identify evidence gaps that must be addressed, such as operational research needs for products with complex delivery requirements [51]. FPHVPs are being developed for vaccine targets such as GBS, ETEC, and herpes simplex virus, and additional FPHVPs are being considered.…”

Section: Full Public Health Value Propositionsmentioning

confidence: 99%

Meeting report: Global vaccine and immunization research forum, 2018

Dull¹,

Friede²,

Hwang³

et al. 2019

Vaccine

View full text Add to dashboard Cite

“…Vaccines may have value to stakeholders beyond healthcare decision-makers and consequently, the value measurement must be broader than the clinical gain. A range of outcome measures linked to additional analysis methods are needed to account for the variation in economic and healthcare development with the introduction of vaccines [6,7]. Vaccines are meaningfully evaluated in terms of avoiding or reducing risk for losing some quality-adjusted life-years (QALY), using plans and programs that target specific populations to control infection spread [8,9].…”

Section: Introductionmentioning

confidence: 99%

“…This article first summarises the historical setting of economic evaluation of vaccines, as that may indicate the different stakeholders who were/are interested and helps to understand the current context of evaluation. It then reviews the stakeholder list with the focus on the specific benefits sought by each [7,[14][15][16][17]. This is followed by a range of analysis methods for measuring those gains, where we briefly describe how we came to our current findings [18].…”

Section: Introductionmentioning

confidence: 99%

How to assess for the full economic value of vaccines? From past to present, drawing lessons for the future

Standaert

Sauboin

DeAntonio³

et al. 2020

Journal of Market Access & Health Policy

View full text Add to dashboard Cite

Background:Cost-effectiveness analysis (CEA) is the economic analysis method most commonly applied today in the context of replacing one treatment with a new one in a developed healthcare system to improve efficiency. CEA is often requested by local healthcare decisionmakers to grant reimbursement.New preventative interventions, such as new vaccines, may however have much wider benefits inside and outside healthcare, when compared with treatment. These additional benefits include externalities on indirect clinical impact, reallocation of specific healthcare resources, improved quality of care, better productivity, better disease control, better fiscal revenues, and others. But these effects are sometimes difficult to integrate into a meaningful CEA result. They may appear as specific benefits for specific stakeholders, other than the stakeholders in healthcare.Objective: Based on a historical view about the application of economic assessments for vaccines our objective has been to make the inventory of who was/is interested in knowing the economic value of vaccines, in what those different stakeholders are likely to see the benefit from their perspective and how were/are we able to measure those benefits and to report them well. Results: The historical view disclosed a limited interest in the economic assessment of vaccines at start, more than 50 years ago, that was comparable to the assessment of looking for more efficiency in new industries through optimization exercises. Today, we are exposed to a very rich panoply of different stakeholders (n= 16). They have their specific interest in many different facets of the vaccine benefit of which some are well known in the conventional economic analysis (n=9), but most outcomes are hidden and not enough evaluated and reported (n=26). Meanwhile we discovered that many different methods of evaluation have been explored to facilitate the measurement and reporting of the benefits (n=18). Conclusion: Our recommendation for future economic evaluations of new vaccines is therefore to find the right combination among the three entities of stakeholder type selection, outcome measure of interest for each stakeholder, and the right method to apply. We present at the end examples that illustrate how successful this approach can be.

show abstract

Estimating the full public health value of vaccination

Cited by 59 publications

References 56 publications

“Running the Gauntlet”: Formidable challenges in advancing neglected tropical diseases vaccines from development through licensure, and a “Call to Action”

“Running the Gauntlet”: Formidable challenges in advancing neglected tropical diseases vaccines from development through licensure, and a “Call to Action”

Meeting report: Global vaccine and immunization research forum, 2018

How to assess for the full economic value of vaccines? From past to present, drawing lessons for the future

Contact Info

Product

Resources

About